Physician

Jose B. Melo, M.D.

According to 2025 Medicare claims, Jose Melo, M.D. (NPI: 1922014547) practices hematology/oncology in the Fort Lauderdale-Pompano Beach-Sunrise, FL market, with the plurality of this provider's patient population coming from Broward, FL. This provider's primary affiliated billing organization is SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (NPI: 1700891256; TIN: 650577436) and primary practice location at 33322-5426.

Melo's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 544 traditional Medicare patients, billed 131,794 HCPCS/CPT codes, and received $2,105,566 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 3,713 prescription claims across 528 beneficiaries totaling $12,388,496 in drug costs, led by Pomalyst (Pomalidomide). 2018 DME data shows 33 claims. Open Payments data shows 307 records totaling $5,589. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,569,485 to $12,388,496. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	686	164,414	$2,055,584
2016	642	169,016	$2,194,229
2017	667	133,480	$1,774,549
2018	645	139,671	$1,948,726
2019	680	126,811	$1,821,637
2020	598	130,897	$1,775,185
2021	596	182,941	$1,766,941
2022	594	201,984	$2,648,640
2023	559	154,997	$1,767,026
2024	544	131,794	$2,105,566

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	469	3,462	$3,569,485
2016	521	3,504	$5,263,621
2017	509	3,333	$6,491,161
2018	495	3,102	$7,762,589
2019	530	3,530	$9,669,155
2020	574	3,971	$10,776,229
2021	580	3,919	$12,279,813
2022	560	4,105	$13,587,307
2023	511	3,432	$11,372,129
2024	528	3,713	$12,388,496

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	194	$6,285
2016	N/R	N/R	N/R
2017	N/R	121	$4,634
2018	N/R	33	$614
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	329	597	$69
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	71	248	$64
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	97	179	$45
96372	Injection of drug or substance under skin or into muscle	75	291	$11
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	443	1,351	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	86	2,408	$1,981,957
Jakafi	Ruxolitinib Phosphate	64	1,920	$1,120,969
Lenalidomide	Lenalidomide	65	1,820	$956,359
Promacta	Eltrombopag Olamine	65	1,950	$940,835
Xtandi	Enzalutamide	60	1,800	$879,210

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	307	$5,589	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jose B. Melo, M.D.?

Tedicare shows public-source Medicare data for Jose B. Melo, M.D. (NPI 1922014547), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jose B. Melo, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jose B. Melo, M.D.?

Jose B. Melo, M.D. is linked to SOUTH FLORIDA ONCOLOGY AND HEMATOLOGY CONSULTANTS LLC (billing NPI 1700891256) in the available physician profile data.

Does Jose B. Melo, M.D. have Open Payments data?

Jose B. Melo, M.D. has 307 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.